Sidney Kimmel Cancer Center at Thomas Jefferson University

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Surgical Resection and Intraoperative Cesium-131 Brachytherapy for Head and Neck Cancer

Early Phase 1

Completed

Conditions: Recurrent Head and Neck Carcinoma

Interventions: Radiation: Brachytherapy
Drug: Cesium-131
Procedure: Conventional surgery

First Posted Date: 2015-06-10

Last Posted Date: 2024-06-27

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 30

Registration Number: NCT02467738

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy

Withdrawn

Conditions: Stage IA Pancreatic Cancer
Stage IIB Pancreatic Cancer
Stage III Pancreatic Cancer
Stage IV Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma
Stage IB Pancreatic Cancer
Stage IIA Pancreatic Cancer

Interventions: Other: Laboratory Biomarker Analysis
Other: Cytology Specimen Collection Procedure

First Posted Date: 2015-04-10

Last Posted Date: 2017-09-08

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT02414100

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Radiation Therapy and MK-3475 for Patients With Recurrent/Metastatic Head and Neck Cancer, Renal Cell Cancer, Melanoma, and Lung Cancer

Phase 1

Completed

Conditions: Metastatic Renal Cell Cancer
Recurrent Renal Cell Carcinoma
Stage IV Lung Cancer
Head and Neck Squamous Cell Carcinoma
Stage III Renal Cell Cancer
Stage IV Skin Melanoma
Recurrent Head and Neck Carcinoma
Recurrent Lung Carcinoma
Recurrent Skin Carcinoma

Interventions: Radiation: Radiation Therapy (RT)
Drug: MK-3475

First Posted Date: 2014-12-17

Last Posted Date: 2024-02-28

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 41

Registration Number: NCT02318771

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma

Phase 1

Withdrawn

Conditions: Plasma Cell Leukemia
Multiple Myeloma

Interventions: Drug: Bendamustine

First Posted Date: 2014-12-11

Last Posted Date: 2024-02-16

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT02315157

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung Cancer

Completed

Conditions: Stage IVA Squamous Cell Carcinoma of the Larynx
Stage IVA Squamous Cell Carcinoma of the Oropharynx
Stage IVA Verrucous Carcinoma of the Oral Cavity
Stage IVB Verrucous Carcinoma of the Oral Cavity
Stage IVC Squamous Cell Carcinoma of the Oropharynx
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma
Stage IVB Squamous Cell Carcinoma of the Larynx
Stage IVC Salivary Gland Cancer
Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
Stage IVC Verrucous Carcinoma of the Larynx

Interventions: Other: Cytology specimen
Other: Laboratory biomarker analysis

First Posted Date: 2014-09-19

Last Posted Date: 2024-02-16

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 130

Registration Number: NCT02245100

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

Phase 2

Completed

Conditions: Stage II Multiple Myeloma
Stage I Multiple Myeloma
Stage III Multiple Myeloma

Interventions: Drug: Bendamustine hydrochloride
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2014-08-25

Last Posted Date: 2019-09-13

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 24

Registration Number: NCT02224729

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas

Phase 1

Completed

Conditions: Adult Brain Stem Glioma
Adult Diffuse Astrocytoma
Adult Giant Cell Glioblastoma
Adult Gliosarcoma
Adult Mixed Glioma
Adult Anaplastic Astrocytoma
Adult Glioblastoma
Adult Subependymal Giant Cell Astrocytoma
Recurrent Adult Brain Tumor
Adult Anaplastic Ependymoma

Interventions: Radiation: Hyperfractionated radiation therapy
Radiation: Stereotactic radiosurgery
Drug: Alisertib
Procedure: Quality-of-life assessment

First Posted Date: 2014-07-10

Last Posted Date: 2023-09-07

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 17

Registration Number: NCT02186509

Locations: 🇺🇸
Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Brief Mindful Meditation Practice in Improving Quality of Life in Patients With Cancer Undergoing Radiation Therapy

Not Applicable

Terminated

Conditions: Malignant Neoplasm

Interventions: Procedure: Meditation therapy
Other: Quality-of-life assessment
Other: Questionnaire administration

First Posted Date: 2014-06-23

Last Posted Date: 2018-05-11

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 17

Registration Number: NCT02170350

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Measuring Biomarker Response to AMP-514 in Blood Samples From Patients With Solid Tumors Undergoing Radiotherapy

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Other: Cytology specimen
Other: Laboratory biomarker analysis

First Posted Date: 2014-06-02

Last Posted Date: 2017-09-06

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 21

Registration Number: NCT02153151

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

Phase 1

Withdrawn

Conditions: Recurrent Melanoma
Stage IV Melanoma
Tumors Metastatic to Brain

Interventions: Drug: Vemurafenib
Radiation: Whole-brain radiation therapy (WBRT)
Radiation: Radiosurgery (SRS)

First Posted Date: 2014-05-23

Last Posted Date: 2016-10-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Registration Number: NCT02145910

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy